{"adverse_reactions":["6 ADVERSE REACTIONS"],"clinical_pharmacology":["12 CLINCIAL PHARMACOLOGY"],"clinical_studies":["14 CLINICAL STUDIES"],"contraindications":["4 CONTRAINDICATIONS"],"description":["11 DESCRIPTION"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION"],"dosage_forms_and_strengths":["3 DOSAGE FORM AND STRENGTH"],"drug_abuse_and_dependence":["9 DRUG ABUSE AND DEPENDENCE"],"drug_interactions":["7 DRUG INTERACTIONS"],"effective_time":"20160413","general_precautions":["17 PATIENT COUNSELING INFORMATION"],"id":"305fa9bc-9752-0aad-e054-00144ff88e88","indications_and_usage":["1 INDICATIONS AND USAGE"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY"],"openfda":{},"overdosage":["10 OVERDOSAGE"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL CARISOPRODOL C-IV 350mg"],"set_id":"305fa9bc-9751-0aad-e054-00144ff88e88","spl_product_data_elements":["CARISOPRODOL CARISOPRODOL CARISOPRODOL CARISOPRODOL HYDROXYPROPYL CELLULOSE (TYPE H) ANHYDROUS LACTOSE STARCH, CORN MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO CELLULOSE, MICROCRYSTALLINE SODIUM LAURYL SULFATE CL;022"],"storage_and_handling":["15 STORAGE AND HANDLING"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATION"],"version":"1","warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS"]}